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Background
In Germany, 17% of 59,000 persons living with HIV/AIDS
are female. Accordingly, the research focus in clinical stud-
ies as well as in cohort analyses has been almost exclu-
sively on HIV-positive men. As a consequence, there is an
urgent need to characterize and evaluate the outcome of
HAART in HIV-positive women and to identify special
requirements of this particular patient population.
Methods
Cross-sectional multicentre (n = 31 centres) evaluation to
observe characteristics of 1,557 HIV-positive women
receiving medical care in Germany between June 2007
and March 2008. Data acquisition was performed using
standardized questionnaires.
Summary of results
Of 1,557 HIV-positive women studied, 1,191 (77%)
received HAART. Mean age was 40 years and average time
of known HIV-infection was 9 years. Risk of HIV transmis-
sion was: 40% heterosexual intercourse in Germany, 36%
heterosexual intercourse in a high prevalence country;
17% IDU; 7% other reasons for transmission. 46% of the
women had a migration background. Mean time on
antiretroviral treatment was 7 years. 53% of the female
participants had been treated with >2 HAART-regimens.
47% of the study subjects received a PI-based regimen,
33% a NNRTI-based regimen; 20% were on other combi-
nations. The most commonly used PI and NNRTI were
lopinavir/r and nevirapine, respectively. Only 48% of all
women under HAART achieved a viral load <40 copies/
ml. There was a significant difference between the PI-
treated group with 44% patients <40 copies/ml and the
NNRTI-treated group with 56% <40 copies/ml (p =
0.003).
Conclusion
We found that HIV-positive women depicted an inferior
virological response to HAART compared to those previ-
ously published in German cohort analyses dominated by
men (response rates >75%). Possible differences in adher-
ence or drug resistance may have impacted these results
and are currently being evaluated in ongoing sub-analy-
ses. Of note, the lack of a study arm with male patients is
a limitation of this investigation. However, this is partly
off-set by the fact that there are good comparative data in
the male population found in other cohorts. We conclude
that our results are in discordance to the popular assump-
tion that there are no gender specific differences in viro-
logical treatment outcome of HAART.
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